Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer

PURPOSE: The purpose of this study was to compare treatment outcomes between combined gonadotropin-releasing hormone agonist and tamoxifen (GnRHa+T) and sequential adriamycin and cyclophosphamide chemotherapy and tamoxifen (AC->T) in premenopausal patients with hormone-responsive, lymph-node–nega...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Res Treat
Autors principals: Sohn, Guiyun, Ahn, Sei Hyun, Kim, Hee Jeong, Son, Byung-Ho, Lee, Jong Won, Ko, Beom Seok, Lee, Yura, Lee, Sae Byul, Baek, Seunghee
Format: Artigo
Idioma:Inglês
Publicat: Korean Cancer Association 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5080815/
https://ncbi.nlm.nih.gov/pubmed/27063654
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2015.444
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars